company background image
BVNK.F logo

Bavarian Nordic OTCPK:BVNK.F Stock Report

Last Price

US$24.24

Market Cap

US$1.8b

7D

0%

1Y

-6.8%

Updated

25 Mar, 2024

Data

Company Financials +

Bavarian Nordic A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bavarian Nordic
Historical stock prices
Current Share Pricekr.24.24
52 Week Highkr.32.05
52 Week Lowkr.17.45
Beta1.34
1 Month Change-2.69%
3 Month Change-6.77%
1 Year Change-6.77%
3 Year Change-46.13%
5 Year Change17.90%
Change since IPO-30.04%

Recent News & Updates

Recent updates

Shareholder Returns

BVNK.FUS BiotechsUS Market
7D0%-0.06%2.1%
1Y-6.8%9.8%30.4%

Return vs Industry: BVNK.F underperformed the US Biotechs industry which returned 9.8% over the past year.

Return vs Market: BVNK.F underperformed the US Market which returned 30.4% over the past year.

Price Volatility

Is BVNK.F's price volatile compared to industry and market?
BVNK.F volatility
BVNK.F Average Weekly Movementn/a
Biotechs Industry Average Movement11.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.0%

Stable Share Price: BVNK.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine BVNK.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19921,379Paul Chaplinhttps://www.bavarian-nordic.com

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.

Bavarian Nordic A/S Fundamentals Summary

How do Bavarian Nordic's earnings and revenue compare to its market cap?
BVNK.F fundamental statistics
Market capUS$1.77b
Earnings (TTM)US$214.06m
Revenue (TTM)US$1.02b

8.3x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BVNK.F income statement (TTM)
Revenuekr.7.06b
Cost of Revenuekr.1.90b
Gross Profitkr.5.16b
Other Expenseskr.3.69b
Earningskr.1.48b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 08, 2024

Earnings per share (EPS)18.93
Gross Margin73.07%
Net Profit Margin20.89%
Debt/Equity Ratio0.2%

How did BVNK.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.